Insight Molecular Diagnostics Inc. (IMDX)
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $4.1M
- Net income
- -$50.2M
- Total assets
- $25.8M
- Market cap
- $169.2M
- Gross margin
- 56.7%
- Operating margin
- -1260.8%
- Net margin
- -1238.5%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $4.1M
- Cost of revenue
- $1.8M
- Gross profit
- $2.3M
- Operating expenses
- $53.4M
- Operating income
- -$51.1M
- Income tax
- $0
- Net income
- -$50.2M
- EPS (basic)
- $-1.65
- EPS (diluted)
- $-1.65
Balance sheet
- Total assets
- $25.8M
- Current assets
- $15.3M
- Total liabilities
- $57.2M
- Current liabilities
- $12.1M
- Shareholders’ equity
- -$31.5M
Cash flow
- Operating cash flow
- -$22.2M
- Investing cash flow
- -$3.2M
- Financing cash flow
- $28.1M
- Net cash flow
- $2.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $169.2M
- EPS (diluted)
- $-1.65
- Shares outstanding
- 35.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 30, 2015
Insight Molecular Diagnostics Inc. (IMDX) Stock Price
- Reported a net loss of $50.2M in FY2025.
- Gross margin of 56.7%, net margin -1238.5%.
- Trading 44% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Insight Molecular Diagnostics Inc..
Write a review
News about Insight Molecular Diagnostics Inc.
News & sentiment via Polygon.io
Insight Molecular Diagnostics Inc.: frequently asked questions
Is Insight Molecular Diagnostics Inc. an American company?
Insight Molecular Diagnostics Inc. is a US-based company headquartered in Nashville, Tennessee, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Insight Molecular Diagnostics Inc. headquartered?
Insight Molecular Diagnostics Inc. is headquartered in Nashville, Tennessee, United States.
Is Insight Molecular Diagnostics Inc. publicly traded?
Yes — Insight Molecular Diagnostics Inc. is a publicly traded company. Its stock trades under the ticker symbol IMDX on the NASDAQ.
What does Insight Molecular Diagnostics Inc. do?
Insight Molecular Diagnostics Inc. is an American Medical Devices company in the Health & Beauty sector.
